{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:31:06Z","timestamp":1791088266436,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.amjcard.2010.01.003","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T04:42:32Z","timestamp":1270010552000},"page":"1413-1419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia"],"prefix":"10.1016","volume":"105","clinical-trial-number":[{"clinical-trial-number":"nct00281008","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00477594","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fatima","family":"Akdim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje E.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Tribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann D.","family":"Flaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2010.01.003_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the national cholesterol education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2010.01.003_bib2","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2010.01.003_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib4","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25","author":"Marais","year":"2004","journal-title":"Clin Biochim Rev"},{"key":"10.1016\/j.amjcard.2010.01.003_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2010.01.003_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2010.01.003_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.amjcard.2003.08.009","article-title":"Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia","volume":"92","author":"Stein","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib8","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2010.01.003_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00129784-200808040-00003","article-title":"Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins","volume":"8","author":"El Harchaoui","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2010.01.003_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MOL.0b013e3282f169c6","article-title":"New targets and emerging therapies for reducing LDL cholesterol","volume":"18","author":"Lilly","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib11","series-title":"Antisense Drug Technology; Principles, Strategies and Applications, 2nd ed","first-page":"273","article-title":"Pharmacological properties of 2\u2032-O-(2-methoxyethyl)-modified antisense oligonucleotides","author":"Bennett","year":"2007"},{"key":"10.1016\/j.amjcard.2010.01.003_bib12","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/nbt915","article-title":"Approaches for the sequence-specific knockdown of mRNA","volume":"21","author":"Scherer","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib13","series-title":"Antisense Drug Technology; Principles, Strategies and Applications, 2nd ed","first-page":"601","article-title":"Cardiovascular therapeutic applications","author":"Crooke","year":"2007"},{"key":"10.1016\/j.amjcard.2010.01.003_bib14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2010.01.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(99)00083-9","article-title":"Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver","volume":"1440","author":"Davis","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.amjcard.2010.01.003_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2010.01.003_bib17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.amjcard.2010.01.003_bib18","first-page":"333A","article-title":"Statin-like, dose-dependent reductions in LDL-C and apolipoprotein B with Isis 301012, an antisense inhibitor of apolipoprotein B, in subjects with polygenic hypercholesterolemia","volume":"49","author":"Stein","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.amjcard.2010.01.003_bib19","first-page":"393A","article-title":"ISIS 301012, an antisense inhibitor of apolipoprotein B, produces significant additional reduction of LDL-C and apolipoprotein B in hypercholesterolemic subjects on statins not meeting target","volume":"49","author":"Kastelein","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2010.01.003_bib21","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2010.01.003_bib23","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein(a) as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2010.01.003_bib24","doi-asserted-by":"crossref","first-page":"44B","DOI":"10.1016\/j.amjcard.2008.02.031","article-title":"Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations","volume":"101","author":"Scanu","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/fampra\/17.6.497","article-title":"The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women","volume":"17","author":"Seed","year":"2000","journal-title":"Fam Pract"},{"key":"10.1016\/j.amjcard.2010.01.003_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2796.1991.tb00483.x","article-title":"N-acetylcysteine and serum concentrations of lipoprotein(a)","volume":"230","author":"Kroon","year":"1991","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2010.01.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(03)00885-3","article-title":"Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)","volume":"92","author":"Farnier","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib28","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","article-title":"The prevalence and etiology of elevated aminotranferase levels in the United States","volume":"98","author":"Clark","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjcard.2010.01.003_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2010.01.003_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2010.01.003_bib32","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2010.01.003_bib33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2010.01.003_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","article-title":"Lack of pharmacokinetic interaction for ISIS 301012, a 2\u2032-O-methoxyethyl modified antisense oligonucleotide targeting apoB-100 mRNA, with oral lipid-lowering agents, simvastatin and ezetimibe, when co-administered in healthy human subjects","volume":"48","author":"Yu","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.amjcard.2010.01.003_bib35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human Apo B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914910000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914910000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:20:27Z","timestamp":1757571627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914910000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0002914910000743"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2010.01.003","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2010.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}